Literature DB >> 11444405

Clostridium difficile-associated diarrhea and colitis.

S F Yassin1, T M Young-Fadok, N N Zein, D S Pardi.   

Abstract

Clostridium difficile is a spore-forming toxigenic bacterium that causes diarrhea and colitis, typically after the use of broad-spectrum antibiotics. The clinical presentation ranges from self-limited diarrhea to fulminant colitis and toxic megacolon. The incidence of this disease is increasing, resulting in major medical and economic consequences. Although most cases respond quickly to medical treatment, C difficile colitis may be serious, especially if diagnosis and treatment are delayed. Recurrent disease represents a particularly challenging problem. Prevention is best accomplished by limiting the use of broad-spectrum antibiotics and following good hygienic techniques and universal precautions to limit the transmission of bacteria. A high index of suspicion results in early diagnosis and treatment and potentially reduces the incidence of complications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444405     DOI: 10.4065/76.7.725

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  16 in total

1.  Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Authors:  Kim L Credito; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 2.  Pathogenesis and treatment of Clostridium difficile infection.

Authors:  I Tonna; P D Welsby
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

Review 3.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

4.  Association of pseudomembranous colitis with Henoch-Schönlein purpura.

Authors:  Takehiko Hayakawa; Hiroyuki Imaeda; Mitsuyasu Nakamura; Shunsuke Komoto; Kazuo Maruta; Hidetoshi Shiozu; Haruhiko Ogata; Yasushi Iwao; Hiromasa Ishii; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2005-06       Impact factor: 7.527

Review 5.  Clostridium difficile infection: clinical spectrum and approach to management.

Authors:  Chetana Vaishnavi
Journal:  Indian J Gastroenterol       Date:  2011-12-20

6.  Clostridium difficile as a cause of healthcare-associated diarrhoea among children in Auckland, New Zealand: clinical and molecular epidemiology.

Authors:  V Sathyendran; G N McAuliffe; T Swager; J T Freeman; S L Taylor; S A Roberts
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-09       Impact factor: 3.267

7.  A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

Authors:  Jennifer Peppe; Andrew Porzio; David M Davidson
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

Review 8.  Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy.

Authors:  Munshi Moyenuddin; John C Williamson; Christopher A Ohl
Journal:  Curr Gastroenterol Rep       Date:  2002-08

9.  Long-term follow-up of patients with fulminant Clostridium difficile colitis.

Authors:  Aaron T Miller; Parissa Tabrizian; Alexander J Greenstein; Andrew Dikman; John Byrn; Celia Divino
Journal:  J Gastrointest Surg       Date:  2009-02-18       Impact factor: 3.452

10.  Epidemic Clostridium difficile strains demonstrate increased competitive fitness compared to nonepidemic isolates.

Authors:  Catherine D Robinson; Jennifer M Auchtung; James Collins; Robert A Britton
Journal:  Infect Immun       Date:  2014-04-14       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.